Comparative Pharmacology
Head-to-head clinical analysis: AZOPT versus KEVEYIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZOPT versus KEVEYIS.
AZOPT vs KEVEYIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbonic anhydrase inhibitor; inhibits carbonic anhydrase II (CA-II) in ciliary processes, reducing aqueous humor secretion and intraocular pressure.
Keveyis (dichlorphenamide) is a carbonic anhydrase inhibitor. It reduces the frequency of attacks in primary hyperkalemic periodic paralysis by decreasing intracellular pH, which stabilizes muscle cell membranes and reduces potassium efflux from muscle cells.
One drop in the affected eye(s) twice daily. Instill at least 10 minutes apart from other ophthalmic medications.
50 mg orally twice daily with food; may increase to 100 mg twice daily after 2 weeks if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 111 minutes (1.85 hours) in plasma after topical ocular administration; prolonged in renal impairment (creatinine clearance <30 mL/min).
Terminal elimination half-life: 15–20 hours following a single oral dose; at steady state, half-life 42–80 hours (mean ~60 h) due to dose-dependent kinetics.
Primarily renal excretion as unchanged drug (approximately 70% of a topically applied dose is absorbed systemically and excreted unchanged in urine); minimal biliary/fecal elimination (<5%).
Primarily renal: unchanged drug accounts for ~82% of dose in urine; fecal excretion <5%; minor hepatic metabolism.
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor